Data Sheet (Cat.No.T28788)

TargetMol

SK-216

Chemical Properties



CAS No. :	654080-03-2
Formula:	C29H29NNa2O6
Molecular Weight:	533.52
Storage:	Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	SK-216, a specific PAI-1 inhibitor, reduces tumor angiogenesis and inhibits VEGF-induced migration and tube formation of human umbilical vein endothelial cells in vitro. This compound also alleviates bleomycin-induced pulmonary fibrosis in mice.
Targets(IC50)	PAI-1
In vitro	**Methods**: Human osteosarcoma cell line 143B was treated with SK-216 (0-50 μM, hours), and the expression of target proteins was detected by Western blot. **Results**: SK-216 at concentrations of 25 and 50 μM inhibited PAI-1 expression by 40%, resulting in a significant decrease in the ratio of cell invasion pores to total pores, and was able to inhibit the secretion of MMP-13 in 143B cells. [2]
In vivo	**Methods**: SK-216 (6.6 μg/200 μL, intraperitoneal injection, once every three days) was used to treat a mouse model of spontaneous lung metastasis to examine whether it inhibits the lung metastasis of human osteosarcoma cells. **Results**: SK-216 inhibited the lung metastasis of human osteosarcoma cells from the primary lesion, but did not inhibit tumor growth. [2]

Solubility Information

Solubility	H2O: 5.38 mg/mL (10.08 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8743 mL	9.3717 mL	18.7434 mL
5 mM	0.3749 mL	1.8743 mL	3.7487 mL
10 mM	0.1874 mL	0.9372 mL	1.8743 mL
50 mM	0.0375 mL	0.1874 mL	0.3749 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Takayama Y, et al. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma. Cancer Res. 2016 Jun 1;76(11):3285-94.

Omori K, et al. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts. PLoS One. 2016 Feb 9;11(2):e0148969. doi: 10.1371/journal.pone.0148969. eCollection 2016. PubMed PMID: 26859294; PubMed Central PMCID: PMC4747467.

Masuda T, et al. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol Cancer Ther. 2013 Nov;12(11):2378-88.

Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, Ueda K, Sugimura T, Wakabayashi K. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis. 2008 Apr;29(4):824-9.